Yamanouchi's Foray Into Drug Delivery
Executive SummaryYamanouchi attempts to use its drug delivery business (Yamanouchi Shaklee Pharma) to help jumpstart its efforts to gain a foothold in the US and to eventually become a true global player. Yamanouchi's support of YSP may, however, be a two-edged sword: it provides YSP with the kind of financial support that most drug delivery companies can only dream of, but it may also scare off potential partners.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.